Benjamin EJ, Levy D, Vaziri SM, et al. 1994. Independent risk factors for atrial ﬁbrillation in a population based cohort:the Framingham heart study. J Am Med Assoc, 271:840–4. Benjamin EJ, Wolf PA, D’Agostino RB, et al. 1998. Impact of atrial ﬁbril- lation on the risk of death: the Framingham heart study. Circulation, 98:946–52. Bungard TJ, Ghali WA, Teo KK, et al. 2000. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med, 160:41–6. Burton JH, Vinson DR, Drummond K, et al. 2004. Electrical cardioversion of emergency department patients with atrial ﬁbrillation. Ann Emerg Med, 44:20–30. Carlsson J, Miketic S, Windeler JS, et al. 2003. Randomized trial of rate-control versus rhythm-control in persistent atrial ﬁbrillation: the strategies of treatment of atrial ﬁbrillation (STAF) Study. J Am Coll Cardiol, 41:1690–6. Collins LJ, Silverman DI, Douglas PS et al. 1995. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic compli- cations with 4 weeks of precardioversion anticoagulation are related toatrial thrombus resolution. Circulation, 92:160–3. Corley SD, Epstein AE, DiMarco JP, et al. 2004 Relationships between sinus rhythm, treatment, and survival in the atrial ﬁbrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation, 109:1509–13. Crystal E, Connolly SJ, Ginger T, et al. 2003. Interventions for preventing post-operative atrial ﬁbrillation in patients undergoing heart surgery. The Cochrane Library. David D, Di Segni E, Klein HO, Kaplinsky E, et al. 1979. Inefﬁciency of digitalis in the control of heart rate in patients with chronic atrial ﬁbril- lation: beneﬁcial effects of an added beta-adrenergic blocking agent. Am J Cardiol, 44:1378–1382. Dmochowska-Perz M, Loboz-Grudzien K, Sokalski L, et al. 2002. Factors predicting recurrence of atrial ﬁbrillation after cardioversion. Kardio- logia Polska, 57:501–11. Dogan A, Avsar A, Ozturk M, et al. 2004 P-wave dispersion for predicting maintenance of sinus rhythm after cardioversion of atrial ﬁbrillation. Am J Cardiol, 93:368–71. Evans A, Perez I, Yu G, Kalra L. 2001. Should stroke subtype inﬂuence anticoagulation decisions to prevent recurrence in stroke patients with atrial ﬁbrillation? Stroke, 32:2828–32. [EAFT] European Atrial Fibrillation Study Group. 1993. Secondary preven- tion in non rheumatic atrial ﬁbrillation after transient ischaemic attack or minor stroke. Lancet, 342:1255–62. Ezekowitz MD, Laupacis A, Boysen G, et al. 1998. Echocardiographic predictors of stroke in patients with atrial ﬁbrillation: A prospec- tive study of 1066 patients from 3 clinical trials. Arch Intern Med, 158:1316–20. Fang MC, Stafford RS, Ruskin JN, et al. 2004. National trends in anti- arryhthmic and anti-thrombotic medication use in atrial ﬁbrillation. Arch Intern Med, 164:55–60. Farshi R, Kistner D, Sarma JS, et al. 1999. Ventricular rate control in chronic atrial ﬁbrillation during daily activity and programmed exercise: a crossover open-label study of ﬁve drug regimens. J Am Coll Cardiol, 33:304–10. Fitzmaurice DA, Murray ET, McCahon D et al. 2005. Self management of oral anticoagulation: randomised trial. BM J, 331:1057. Freestone B, Lip GYH. 2003. Epidemiology and costs of Cardiac Arrhyth- mias. In: Lip GYH, Godtfredson J, eds. Cardiac arryhythmias: a clinical approach. Edinburgh: Mosby. pp 3-24. Frick M, Frykman V, Jensen-Urstad M, et al. 2001. Factors predicting success rate and recurrence of atrial ﬁbrillation after ﬁrst electrical cardioversion in patients with persistent atrial ﬁbrillation. Clin Cardiol, 24:238–44. Galperin J, Elizari MV, Chiale PA, et al. 2003. Pharmacologic re- version of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance. J Cardiovas Pharmacol Ther, 8:179–86. Vascular Health and Risk Management 2007:3(1) Atrial ﬁbrillation Fuster V, Ryden LE, Asinger RW, et al. 2001. American College of Car- diology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial ﬁbrillation: executive summary a report of the American College of Cardiology/American heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial ﬁbrillation) de- veloped in collaboration with the North American Society of Pacing and Electrophysiology. Circulation, 104:2118. Fuster V, Rydén L.E, David S, et al. 2006. ACC/AHA/ESC 2006 Guide- lines for the Management of Patients With atrial ﬁbrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With atrial ﬁbrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circula- tion, 114:e257–e354. Gage BF, Waterman AD, Shannon W, et al. 2001. Validation of clinical classiﬁcation schemes for predicting stroke: results from the National Registry of atrial ﬁbrillation. JAMA, 285:2864–2870. Go AS, Hylek EM, Phillips KA. 2001. Prevalence of diagnosed atrial ﬁbril- lation in adults, national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial ﬁbrillation ( ATRIA ) study. JAMA, 285:2370–5. Gronefeld GC, Lilienthal J, Kuck KH, et al. 2003. Pharmacological intervention in atrial fibrillation. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibril- lation. Results from a prospective randomized study. Eur Heart J, 24:1430–6. Hart RG, Benavente O, McBride R, et al. 1999. Antithrombotic therapy to prevent stroke in patients with atrial ﬁbrillation: a meta-analysis. Ann intern Med, 131:492–501. Hart RG, Pearce LA, Rothbart RM, et al. 2000. Stroke with intermittent atrial ﬁbrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Car- diol, 35:183–7. Hohnloser SH, Kuck KH. 2001. Randomized trial of rhythm or rate control in atrial ﬁbrillation: the Pharmacological intervention in atrial ﬁbrilla- tion trial (PIAF). Eur Heart J, 22:801–2. Kamp O, Verhorst PMJ, Welling RC, et al. 1999. Importance of left atrial appendage ﬂow as a predictor of thromboembolic events in patients with atrial ﬁbrillation. Eur Heart J, 20:979–85. Kawaguchi AT, Kosakai Y, Sasako Y, et al. 1996. Risks and beneﬁts of combined maze procedure for atrial ﬁbrillation associated with organic heart disease. J Am Coll Cardiol, 28:985–90. Kinlay S, Leitch JW, Neil A, et al. 1996. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in patients with palpitations. A controlled clinical trial. Ann Inter Med, 124:16–20. Klein AL, Grimm RA, Murray RD, et al. 2001. Use of transesophageal echocardiography to guide cardioversion in patients with atrial ﬁbril- lation. N Engl J Med, 344:1411–20. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. 2004. Long-term maintenance of normal sinus rhythm in patients with current symptom- atic atrial ﬁbrillation: amiodarone vs propafenone, both in low doses. Chest, 125:377–83. Lardoux H, Mallet A, et al. 2001. FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane) Investigators. Antico- agulant (ﬂuindione)-aspirin combination in patients with high-risk atrial ﬁbrillation. A randomized trial (Fluindione, Fibrillation Au- riculaire, Aspirin et Contraste Spontane, FFAACS). Cerebrovasc Dis, 12:245–52. Lee JK, Klein GJ, Krahn AD, et al. 2003. Rate-control versus conversion strategy in postoperative atrial ﬁbrillation: trial design and pilot study results. Card Electrophysiol Rev, 7:178–84. 115